Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 200Thoracic 112CNS 106Breast 90Gynecologic 87Genitourinary 54Sarcoma 50Dermatologic 20Tumor-Agnostic 14Lymphoid 12Head & Neck 12Endocrine 7Other solid neoplasm 5Other hematologic neoplasm 5Plasma cell 3NET 3Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Bevacizumab × Plasma cell × Clear all
NCT00410605 2017-09-01

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
39 enrolled 10 charts
Plasma cell

Multiple Myeloma

NCT00473590 2017-06-14

AMBER

Genentech, Inc.

Phase 2 Completed
102 enrolled 13 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02079519 2014-07-08

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Hoffmann-La Roche

Phase 2 Terminated
10 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡